A Systematic Follow-Up of Mycobacterium tuberculosis Drug-Resistance and Associated Genotypic Lineages in the French Departments of the Americas over a Seventeen-Year Period
| Autor: | Delaina Paasch, Mylène Berchel, Julie Millet, Franziska Schuster, Elisabeth Streit, Anne-Gaël Bomer, G. Cadelis, Jessica Vanhomwegen, Nalin Rastogi |
|---|---|
| Přispěvatelé: | Institut Pasteur de la Guadeloupe, Réseau International des Instituts Pasteur (RIIP), Centre de lutte antituberculeux de la Guadeloupe, CHU Pointe-à-Pitre/Abymes [Guadeloupe], Service de Pneumologie |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Tuberculosis Genotype Article Subject Population Antitubercular Agents lcsh:Medicine Drug resistance Biology General Biochemistry Genetics and Molecular Biology Mycobacterium tuberculosis Internal medicine Tuberculosis Multidrug-Resistant medicine Humans education Phylogeny education.field_of_study General Immunology and Microbiology business.industry Isoniazid lcsh:R General Medicine medicine.disease biology.organism_classification [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology 3. Good health Biotechnology High incidence Americas business Rifampicin medicine.drug Research Article Follow-Up Studies |
| Zdroj: | BioMed Research International BioMed Research International, Hindawi Publishing Corporation, 2014, 2014, Article ID 689852, 14 p. ⟨10.1155/2014/689852⟩ BioMed Research International, Vol 2014 (2014) |
| ISSN: | 2314-6133 2314-6141 |
| DOI: | 10.1155/2014/689852 |
| Popis: | The population of the French Departments of the Americas (FDA) is highly influenced by the intense migratory flows with mainland France and surrounding countries of the Caribbean and Latin America, some of which have high incidence rates of tuberculosis (Haiti: 230/100,000; Guyana: 111/100,000; and Suriname: 145/100,000) and drug resistance. Since the development of drug resistance to conventional antituberculous drugs has a major impact on the treatment success of tuberculosis, we therefore decided to review carefullyMycobacterium tuberculosisdrug resistance and associated genotypic lineages in the FDA over a seventeen-year period (January 1995–December 2011). A total of 1239 cases were studied, including 153 drug-resistant and 26 multidrug-resistant- (MDR-) TB cases, representing 12.3% and 2.1% of the TB cases in our study setting. A significantly higher proportion ofM. tuberculosisisolates among relapse cases showed drug resistance to isoniazid (22.5%,P=0.002), rifampicin (20.0%,P<0.001), or both (MDR-TB, 17.5%;P<0.001). Determination of spoligotyping based phylogenetic clades showed that among the five major lineages observed—T family (30.1%); Latin-American and Mediterranean (LAM, 23.7%); Haarlem (H, 22.2%); East-African Indian (EAI, 7.2%); and X family (6.5%)—two lineages, X and LAM, were overrepresented in drug-resistant and MDR-TB cases, respectively. Finally, 19 predominant spoligotypes were identified for the 1239 isolates ofM. tuberculosisin our study among which 4 were significantly associated with drug resistance corresponding to SIT20/LAM1, SIT64/LAM6, SIT45/H1, and SIT46/undefined lineage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|